Akeso Biomedical files dossier to market non-antibiotic feed additive
The company's TYPLEX Chelate is designed to improve animal intestinal health, nutrient absorption and reduce infections by pathogens
Akeso Biomedical has filed a dossier with the European Commission to market TYPLEX Chelate as a zootechnical feed additive for all avian species. Akeso's feed additives are based on its Fe3C technology and are designed to improve animal intestinal health and nutrient absorption and reduce infections by pathogens, including Salmonella spp., Campylocbacter jejuni, E. coli, and Clostridium perfringens, among others.
Akeso has shown that TYPLEX Chelate, the company's first commercial product, significantly reduces the ability of numerous infectious pathogens to adhere to the intestinal lining of birds. Since the bacteria cannot attach, they are eliminated by gut peristalsis. The consequent reduction in gut populations of undesirable microorganisms allows birds to devote more energy to healthy growth rather than fighting off harmful bacteria.
Sarah Foulger, Managing Director of Banham Poultry Ltd in the UK, said, “We have been working hard with Akeso to support the development of TYPLEX Chelate by facilitating exclusive commercial trials, and we are eager to begin using it in our broiler production.”